Company Encyclopedia
View More
name
JZYY
600750.SH
Jiang Zhong Pharmaceutical Co.,Ltd engages in the manufacture of pharmaceutical products in China. The company offers OTC products, including stomach-strengthening and digestion-promoting tablets, lactobacillus tablets, triple live bifidobacterium enteric-coated capsules, compound fresh bamboo juice liquid, compound coral lozenges, multivitamin tablets, Fritillaria and loquat capsules, bezoar and snake gallbladder Fritillaria liquid, and compound gold melon seed. It also provides health consumer and other products, such as nourishing, rehabilitation nutrition, gastrointestinal health, and liver health products. In addition, the company offers prescription drugs comprising traditional Chinese medicine products, which includes Shenbao capsules, Paishi granules, Huangba Shengmai drink, Bazhen Yimu capsules, Zhenju Jiangya tablets, Shuangju granules, Zhikang tablets, Shuxiong granules, etc.; chemical medicine products, such as lumbrokinase enteric-coated capsules, Rabelagat sodium enteric-coated tablets, chloroprocaine hydrochloride, etc.; and medicinal materials which includes stir-fried Chinese jujube seeds, French pinellia, and vinegar-soaked northern bupleurum.
3.157 T
600750.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking21/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE21.94%A
    • Profit Margin19.44%A
    • Gross Margin63.36%A
  • Growth ScoreC
    • Revenue YoY-4.66%D
    • Net Profit YoY6.48%C
    • Total Assets YoY12.48%B
    • Net Assets YoY5.09%B
  • Cash ScoreC
    • Cash Flow Margin514.38%C
    • OCF YoY-4.66%D
  • Operating ScoreB
    • Turnover0.65B
  • Debt ScoreB
    • Gearing Ratio35.46%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    China Resources Pharmaceutical: JZYY's net profit for the first three quarters is 743 million yuan, an increase of 6.02% year-on-year

    According to the Zhitong Finance APP, China Resources Pharmaceutical announced the performance of JZYY for the nine months ending September 30, 2025, with total operating revenue of 2.933 billion RMB, a year-on-year decrease of 6.28%; net profit of 743 million RMB, a year-on-year increase of 6.02%

    Zhitong·
    SH
    600750
    -0.78%
    Zhitong·
    SH
    600750
    -0.78%

    JZYY: The net profit attributable to the parent company in the third quarter was 161 million yuan, an increase of 4.70% year-on-year

    On October 24th, JZYY announced that in the third quarter of 2025, it achieved operating revenue of 792 million yuan, a year-on-year decrease of 7.59%; the net profit attributable to shareholders of the listed company was 161 million yuan, a year-on-year increase of 4.70%; basic earnings per share were 0.26 yuan

    Zhitong·
    SH
    600750
    -0.78%
    Zhitong·
    SH
    600750
    -0.78%

    Zhongtai Securities: The gross profit margin of the Chinese medicine sector is expected to recover in H2 2025, optimistic about leading brands in OTC and innovative pipelines

    Zhongtai Securities released a research report indicating that the gross profit margin of the Chinese medicine sector is expected to recover in the second half of 2025, mainly due to the digestion of high-priced medicinal materials and alleviated cost pressures. Although OTC demand is relatively weak, leading brand OTC products and innovative pipelines still have advantages. In the first half of 2025, the total revenue of Chinese medicine companies is expected to be 172.9 billion yuan, a year-on-year decrease of 4.95%, with a net profit of 19.1 billion yuan, a year-on-year decrease of 9.31%. Overall, the industry's prosperity is gradually recovering, with slight declines in gross profit margin and net profit margin

    Zhitong·
    SH
    600750
    -0.78%
    SZ
    000999
    +0.21%
    SH
    562390
    +0.10%
    Zhitong·
    SH
    600750
    -0.78%
    SZ
    000999
    +0.21%
    SH
    562390
    +0.10%

    The heavy holdings of brokerages in the second quarter have been released, favoring industries such as basic chemicals, machinery and equipment, automobiles, and pharmaceuticals and biotechnology

    With the conclusion of the semi-annual report disclosures of listed companies, the second-quarter heavy positions and changes in holdings of brokerage firms have been revealed. In terms of increased holdings, brokerages have shown a strong preference for industries such as basic chemicals, machinery and equipment, automobiles, and pharmaceuticals and biotechnology, with a total of 63 stocks being increased in the second quarter. CNNC TD, New Mileage, JZYY, and Yuntianhua have all received increased positions. Chanhen, Fuan Energy, Ruida Futures, and Zhejiang Huaye have also been favored by at least three brokerages

    Wallstreetcn·
    SH
    600750
    -0.78%
    SZ
    002145
    0.00%
    SZ
    002895
    +4.22%
    Wallstreetcn·
    SH
    600750
    -0.78%
    SZ
    002145
    0.00%
    SZ
    002895
    +4.22%

    China Resources Pharmaceutical: JZYY's net profit attributable to the parent company in the first half of the year was approximately 522 million yuan, a year-on-year increase of 5.8%

    According to the Zhitong Finance APP, China Resources Pharmaceutical announced the mid-term performance of JZYY for 2025, with total operating revenue of approximately 2.141 billion yuan, a year-on-year decrease of 5.79%; net profit attributable to shareholders of the listed company was approximately 522 million yuan, a year-on-year increase of 5.8%; basic earnings per share were 0.82 yuan, with a cash dividend of 5 yuan (tax included) for every 10 shares

    Zhitong·
    SH
    600750
    -0.78%
    Zhitong·
    SH
    600750
    -0.78%
    © 2025 Longbridge｜Disclaimer